Acadia Pharmaceuticals | ACAD - Assets


Acadia Pharmaceuticals reported $1.61B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
ALKERMES USD 4.39B 135.05M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Cara Therapeutics USD 25.82M 6.26M Mar/2026
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
Eisai JPY 1.56T 108.98B Jun/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Incyte USD 7.87B 533.53M Jun/2026
J&J USD 201.06B 167M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Prothena USD 349.89M 23.09M Mar/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026